Phase 3Active, not recruiting
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy (MAJESTY)
A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy
- Sponsor
- Hoffmann-La Roche (Industry)
- Enrolment
- 142 enrolled
- Conditions
- Primary Membranous Nephropathy
- Interventions
- Obinutuzumab; Tacrolimus; Methylprednisolone; Acetaminophen; Diphenhydramine
- Ages
- adults, older adults
- Registry
- NCT04629248
From the registry
This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).
Primary outcomes
- Percentage of Participants who Achieve a Complete Remission (CR) at Week 104